ES2177543T3 - Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos. - Google Patents

Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos.

Info

Publication number
ES2177543T3
ES2177543T3 ES93907541T ES93907541T ES2177543T3 ES 2177543 T3 ES2177543 T3 ES 2177543T3 ES 93907541 T ES93907541 T ES 93907541T ES 93907541 T ES93907541 T ES 93907541T ES 2177543 T3 ES2177543 T3 ES 2177543T3
Authority
ES
Spain
Prior art keywords
mammals
eye
alpha
administration
alfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907541T
Other languages
English (en)
Inventor
Mussie Elizabeth Wolde
Guadalupe Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2177543T3 publication Critical patent/ES2177543T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS PARA TRATAR GLAUCOMA Y/O HIPERTENSION OCULAR EN EL OJO DE LOS MAMIFEROS POR ADMINISTRACION AL OJO DE LOS MAMIFEROS DE LA COMPOSICION FARMACEUTICA DE LA INVENCION QUE CONTIENE COMO INGREDIENTE ACTIVO UNO O MAS COMPUESTOS ANTAGONISTAS MUSCARINICOS. EJEMPLOS DE ANTAGONISTAS MUSCARINICOS UTILIZADOS EN LA COMPOSICION FARMACEUTICA Y METODO DE TRATAMIENTO SON : 10H TIENO(3,4-B) (1,5)BENZODIAZEPIN NA 4,9 ETIL) (TELENZEPINA); 5,11 DIHIDRO AZINIL) NA (PIRENZEPINA); 11 IDINIL] BENZODIZEPIN IETILAMINO) METIL] 50) DEXTROROTATORIA; UNA SAL OPTALMICAMENTE ACEPTABLE DE 4 IFENILACETOXI OHEXIL, -(ALFA)-FENIL ); CICLOHEXANOMETANOL, (ALFA)-FENIL, (ALFA)-[3-(1 L) PIN NIL] [1,4]BENZODIAZEPINA ILAMINO)METIL] MONOMETANOSULFONATO (AF-DX 384); 1,8 BIS [6 RURO (METOCTRAMINA) Y NAFTO[2,3 C] FURAN 3S -[3 (ALFA), 3A (ALFA), 4 (BETA)[1E, 2(2R*, 6S*)],4A (BETA), 8A (ALFA), 9A (ALFA)]] (HIMBACINA).
ES93907541T 1992-03-18 1993-03-16 Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos. Expired - Lifetime ES2177543T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/853,374 US5716952A (en) 1992-03-18 1992-03-18 Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists

Publications (1)

Publication Number Publication Date
ES2177543T3 true ES2177543T3 (es) 2002-12-16

Family

ID=25315868

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907541T Expired - Lifetime ES2177543T3 (es) 1992-03-18 1993-03-16 Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos.

Country Status (8)

Country Link
US (1) US5716952A (es)
EP (1) EP0634932B1 (es)
JP (1) JPH07504915A (es)
AT (1) ATE219367T1 (es)
AU (1) AU666536B2 (es)
DE (1) DE69332048T2 (es)
ES (1) ES2177543T3 (es)
WO (1) WO1993018772A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000229961A (ja) * 1998-12-11 2000-08-22 Sagami Chem Res Center ヒドロナフト［２，３−ｃ］フラン誘導体およびその製造方法
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6164282A (en) * 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
WO2003033501A1 (en) * 2001-10-18 2003-04-24 Schering Corporation Himbacine analogues as thrombin receptor antagonists
KR20070033032A (ko) 2004-07-16 2007-03-23 프로테오시스 악티엔게젤샤프트 세포보호제로서 ｐａｒｐ 및 ｓｉｒ 조절 활성을 갖는무스카린 길항제
US20110294791A1 (en) 2009-01-13 2011-12-01 Proteosys Ag Pirenzepine as an agent in cancer treatment
WO2012108841A1 (en) * 2011-02-09 2012-08-16 Singapore Health Services Pte. Ltd. Transglutaminase-2 inhibitors and uses thereof
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
WO2018209051A1 (en) 2017-05-11 2018-11-15 Nevakar Inc. Atropine pharmaceutical compositions
AU2018371787A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
JP2022539639A (ja) 2020-08-04 2022-09-13 参天製薬株式会社 近視の治療、近視の予防および／または近視の進行抑制のための医薬
WO2022080397A1 (ja) * 2020-10-14 2022-04-21 参天製薬株式会社 安定な医薬組成物
KR20240168375A (ko) * 2022-03-30 2024-11-29 산텐 세이야꾸 가부시키가이샤 고순도 화합물의 제조 방법 및 정제 방법
CN118946362A (zh) 2022-03-30 2024-11-12 参天制药株式会社 医药制剂的灭菌法和包装体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918407A (en) * 1957-04-08 1959-12-22 Lakeside Lab Inc Anti-spasmodics specific for upper gastrointestinal pain and spasm
US3467756A (en) * 1967-03-16 1969-09-16 Merck & Co Inc Composition and method for treating glaucoma
DE1795183B1 (de) * 1968-08-20 1972-07-20 Thomae Gmbh Dr K 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
US4565821A (en) * 1983-03-21 1986-01-21 The Texas A&M University System Method and ophthalmic composition for treating ocular hypertension and glaucoma with butyrophenones
IT1212742B (it) * 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
DE3409237A1 (de) * 1984-03-14 1985-09-19 Dr. Karl Thomae Gmbh, 7950 Biberach Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4886815A (en) * 1984-06-20 1989-12-12 Schachar Ronald A Treatment and prevention of retinal edema with dopaminergic antagonists
DE3626095A1 (de) * 1986-07-31 1988-02-11 Thomae Gmbh Dr K Neue substituierte pyrido(2,3-b)(1,4)benzodiazepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE69033775T2 (de) * 1989-06-21 2001-11-15 Trustees Of The University Of Pennsylvania, Philadelphia Verwendung eines Muskarinantagonists zur Herstellung eines Medikaments für die Behandlung und Regulierung der Augenentwicklung
US5066664A (en) * 1990-02-28 1991-11-19 Allergan, Inc. 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5153205A (en) * 1990-10-01 1992-10-06 Merck & Co., Inc. Method to reduce introacular pressure without causing miosis

Also Published As

Publication number Publication date
US5716952A (en) 1998-02-10
ATE219367T1 (de) 2002-07-15
DE69332048T2 (de) 2003-01-23
AU666536B2 (en) 1996-02-15
WO1993018772A1 (en) 1993-09-30
EP0634932A1 (en) 1995-01-25
EP0634932B1 (en) 2002-06-19
DE69332048D1 (de) 2002-07-25
AU3810993A (en) 1993-10-21
JPH07504915A (ja) 1995-06-01

Similar Documents

Publication Publication Date Title
ES2177543T3 (es) Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de antagonistas muscarinicos.
SV2003000697A (es) Agonistas del receptor beta3-adrenergico y usos de los mismos ref. pc11008/700016/bb
ES2182973T3 (es) Metodo para reducir la presion intraocular enel ojo de mamifero por administracion de bloqueadors de canal de potasio.
PA8591701A1 (es) Derivados de pirrolopirimidina
AR012964A1 (es) Compuetos derivados de bencimidazol, composiciones farmaceuticas que los contienen y su uso en la manufactura de medicamentos para tratar infeccionesvirales
DE69833451D1 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
ES2072323T3 (es) Compuestos de piperidina y su preparacion y empleo.
DE60138222D1 (de) Modulierung von il-2 und il-15 vermittelten t zellantworten
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
SE9904508D0 (sv) New compounds
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
ECSP024364A (es) Antagonistas receptores de adenosina a2a
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
AR018033A1 (es) Analogos 13-oxa prostaglandinas, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
BR0314635A (pt) Derivados de piridina como moduladores de receptores de cb2
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
UY27023A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip
MXPA04000839A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
EP1110554A4 (en) MEDICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
AR009028A1 (es) Composiciones farmaceuticas, un procedimiento para preparar dichas composiciones y utilizacion de dichas composiciones en el tratamiento deenfermedades oftalmicas y metodos para tratar dichas enfermedades
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
AR000509A1 (es) Utilización de un antagonist de sustancia p para la preparación de una composición farmacéutica paratratar algunas enfermedades de la piel de origen neurogeno
AR001931A1 (es) Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos